Protalix BioTherapeutics Inc. (DE) (PLX)
Symbol Info
Listed Symbol PLX
Name Protalix BioTherapeutics Inc. (DE)
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $34,240,000
Latest Fiscal EPS $-0.19
Price Info
21 Day Moving Average $0.2057
21 Day EMA $0.205960
50 Day Moving Average $0.2306
50 Day EMA $0.241830
200 Day EMA $0.357240
200 Day Moving Average 0.378730
52 Week High $0.61
52 Week Low $0.17
52 Week Change $-67.684000
Alpha -0.039476
Beta 2.7361
Standard Deviation 0.213596
R2 0.193717
Periods 60
Share Information
10 Day Average Volume 302,097
20 Day Average Volume 293,999
30 Day Average Volume 256,479
50 Day Average Volume 363,236
Outstanding Shares 148,382,299
Float Shares 143,911,797
Percent Float 96.99%
Short Interest 3,010,897
Short Percent Float 2.00%
Short Interest Ratio 12.68
Short Date 2019-09-13
Holders
Institutions 58
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 1,513,674
Institute Holdings Percent 13.200000
Institute Sold Previous 3 Months 1,195,356
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 1
Insider Holdings Percent 3.00%
Insider Sold Previous 3 Months -
Insiders Shares Owned 4,470,502
Price Change
7 Day Price Change $-0.03225
7 Day Percent Change -15.19%
21 Day Price Change $-0.02
21 Day Percent Change -10.00%
30 Day Price Change $-0.049
30 Day Percent Change -21.40%
Month To Date Price Change $-0.0251
Month To Date Percent -12.24%
90 Day Price Change $-0.2499
90 Day Percent Change -58.13%
Quarter To Date $-0.0251
Quarter To Date Percent -12.24%
180 Day Price Change $-0.2738
180 Day Percent Change -60.33%
200 Day Price Change $-0.2301
200 Day Percent Change -56.11%
Year To Date $-0.131
Year To Date Percent -42.12%
Profile
Description Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa, for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. Its pipeline products include Alidornase Alfa, Pegunigalsidase Alfa, and Oprx-106. The company's primary sources of revenues include its sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.
Details
Issue Type CS
Market Cap $26,708,814
Sec Type EQS
Auditor Kesselman & Kesselman C.P.A.s
Total Shares Outstanding 148,382,299
CEO Dror Bashan
Employees 184
Last Audit UQ
Classification
CIK 0001006281
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 2 Snunit Street
Science Park, POB 455
Carmiel, 20100
Website http://www.protalix.com
Facisimile +972 49889489
Telephone +972 49889488
Email IR@portalix.com
Key Ratios
Profitability
EBIT Margin -40.3
EBITDA Margin -36.7
Pre-Tax Profit Margin -332.1
Profit Margin Cont -41.13
Gross Margin 80.30
Profit Margin TOT -41.13
Income Statements
Revenue $49,704,000
Revenue Per Share $0.3350
Revenue 3 Years $-
Revenue 5 Years $29.56
Valuation Measures
PE Ratio -
Enterprise Value $60,531,209
Price To Sales 0.537357
Price To Free Cash -1.8
PE High Last 5 Years -
Price To Book 24.3
Price To Cash Flow 5.0
PE Low Last 5 Years -
Price To Tangible Book -0.5
Financial Strength
Total Debt To Equity -
Int Coverage -2.4
Current Ratio 1.6
Leverage Ratio -1
Quick Ratio 1.2
Long Term Debt To Capital -
Assets
Receivables Turnover 4.2
Invoice Turnover 1.20
Assets Turnover 0.30
Management Effectiveness
Return Assets -48.17
Return On Equity 44.02
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
AMEX
PLX
Protalix B..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.